Target
flu/cy
1 abstract
Abstract
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.Org: University of Chicago, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, University of Washington/Fred Hutchinson Cancer Research Center, University of Colorado Cancer Center,